Abbott Drops ZoMaxx Stent In Favor Of Xience On Trial Results Slated For TCT
This article was originally published in The Gray Sheet
Executive Summary
Following a review of its most recent trial data, Abbott has decided to refocus its drug-eluting stent development efforts on its recently acquired Xience V system and drop its in-house ZoMaxx stent program
You may also be interested in...
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?
Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C